Search

Your search keyword '"Minami, Hironobu"' showing total 607 results
Start Over Author "Minami, Hironobu" Search Limiters Full Text
607 results on '"Minami, Hironobu"'

2. miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells

Author

Mukohyama, Junko, Isobe, Taichi, Hu, Qingjiang, Hayashi, Takanori, Watanabe, Takashi, Maeda, Masao, Yanagi, Hisano, Qian, Xin, Yamashita, Kimihiro, Minami, Hironobu, Mimori, Koshi, Sahoo, Debashis, Kakeji, Yoshihiro, Suzuki, Akira, Dalerba, Piero, and Shimono, Yohei

Subjects
Genetics, Stem Cell Research, Digestive Diseases, Biotechnology, Cancer, Colo-Rectal Cancer, Clinical Research, 3' Untranslated Regions, Adenocarcinoma, Animals, Cell Line, Tumor, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Genes, Reporter, Heterografts, Humans, Mice, Mice, Inbred NOD, Mice, SCID, MicroRNAs, Neoplasm Proteins, Neoplasm Transplantation, Neoplastic Stem Cells, Organoids, Protein Isoforms, RNA, Neoplasm, RNA-Binding Proteins, Recombinant Proteins, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

miRNAs are key players in the integrated regulation of cellular processes and shape many of the functional properties that define the "cancer stem cell" (CSC) phenotype. Little is known, however, about miRNAs that regulate such properties in human colorectal carcinoma. In this study, we compared the expression levels of 754 miRNAs between paired samples of EpCAM+/CD44+ cancer cells (enriched in CSCs) and EpCAM+/CD44neg cancer cells (with CSC depletion) sorted in parallel from human primary colorectal carcinomas and identified miR-221 as the miRNA that displayed the highest level of preferential expression in EpCAM+/CD44+ cancer cells. High levels of miR-221 expression were associated with Lgr5+ cells in mouse colon crypts and reduced survival in patients with colorectal carcinoma. Constitutive overexpression of miR-221 enhanced organoid-forming capacity of both conventional colorectal carcinoma cell lines and patient-derived xenografts (PDX) in vitro. Importantly, constitutive downregulation of miR-221 suppressed organoid-forming capacity in vitro and substantially reduced the tumorigenic capacity of CSC populations from PDX lines in vivo. Finally, the most abundant splicing isoform of the human Quaking (QKI) gene, QKI-5, was identified as a functional target of miR-221; overexpression of miR-221-reduced QKI-5 protein levels in human colorectal carcinoma cells. As expected, overexpression of QKI-5 suppressed organoid-forming capacity in vitro and tumorigenic capacity of colorectal carcinoma PDX cells in vivo. Our study reveals a mechanistic link between miR-221 and QKI and highlights their key role in regulating CSC properties in human colorectal cancer. SIGNIFICANCE: These findings uncover molecular mechanisms underlying the maintenance of cancer stem cell properties in colon cancer.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/20/5151/F1.large.jpg.

Published
2019

3. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib

Author

Gerds, Aaron T, Tauchi, Tetsuzo, Ritchie, Ellen, Deininger, Michael, Jamieson, Catriona, Mesa, Ruben, Heaney, Mark, Komatsu, Norio, Minami, Hironobu, Su, Yun, Shaik, Naveed, Zhang, Xiaoxi, DiRienzo, Christine, Zeremski, Mirjana, Chan, Geoffrey, and Talpaz, Moshe

Subjects
Brain Disorders, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Chemotherapy, Adjuvant, Female, Humans, Male, Middle Aged, Nitriles, Organ Size, Phenylurea Compounds, Primary Myelofibrosis, Pyrazoles, Pyrimidines, Spleen, Treatment Outcome, Young Adult, Glasdegib, Hedgehog inhibitor, Smoothened inhibitor, Myelofibrosis, Clinical Sciences, Immunology
Abstract

Glasdegib is a potent and selective oral inhibitor of the Hedgehog pathway. We report data from the single-arm, lead-in cohort of an open-label phase 1b/2 trial of glasdegib in patients with primary/secondary myelofibrosis (MF) previously treated with at least one Janus kinase inhibitor (JAKi). Patients received glasdegib 100 mg orally once daily until there was no further clinical benefit. Primary endpoints included adverse events (AEs). Secondary endpoints included patients with spleen volume reduction (SVR) ≥35% at week 24, patients with ≥50% total symptom score (TSS) reduction, and pharmacokinetics. All 21 treated patients had one or more AE and five (23.8%) had serious AEs. Most common (>30%) AEs were dysgeusia (61.9%), muscle spasms (57.1%), alopecia (38.1%), fatigue (33.3%), and decreased appetite (33.3%). Although no patient had ≥35% SVR at week 24, one patient previously treated with ruxolitinib had an SVR of 32.9%. At week 12, two (9.5%) patients had ≥50% reduction in TSS from baseline and ˜40% had ≥20% reduction. One patient had an anaemia response. Following administration of glasdegib 100 mg once daily, the median time to peak plasma concentrations at steady-state generally occurred at 1 h post-dose. The safety profile of glasdegib monotherapy was manageable in patients with primary/secondary MF. Further study of glasdegib in combination with JAKi in a MF population may be warranted.

Published
2019

4. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Author

Rai, Shinya, primary, Kim, Won Seog, additional, Ando, Kiyoshi, additional, Choi, Ilseung, additional, Izutsu, Koji, additional, Tsukamoto, Norifumi, additional, Maruyama, Dai, additional, Tsukasaki, Kunihiro, additional, Kuroda, Junya, additional, Ando, Jun, additional, Hidaka, Michihiro, additional, Koh, Youngil, additional, Kato, Hisashi, additional, Uchida, Toshiki, additional, Yang, Deok Hwan, additional, Ishitsuka, Kenji, additional, Ishizawa, Kenichi, additional, Kim, Jin Seok, additional, Lee, Hong Ghi, additional, Minami, Hironobu, additional, Eom, Hyeon Seok, additional, Kurosawa, Mitsutoshi, additional, Lee, Jae Hoon, additional, Lee, Jong Seok, additional, Lee, Won Sik, additional, Nagai, Hirokazu, additional, Shindo, Takero, additional, Yoon, Dok Hyun, additional, Yoshida, Shinichiro, additional, Gillings, Mireille, additional, Onogi, Hiroshi, additional, and Tobinai, Kensei, additional

Published
2024
Full Text
View/download PDF

5. Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines

Author

Funakoshi, Yohei, primary, Yakushijin, Kimikazu, additional, Ohji, Goh, additional, Matsutani, Takaji, additional, Doi, Kazuhiko, additional, Sakai, Hironori, additional, Sasaki, Tomoki, additional, Kusakabe, Takahiro, additional, Matsumoto, Sakuya, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Koyama, Taiji, additional, Nagatani, Yoshiaki, additional, Kurata, Keiji, additional, Kimbara, Shiro, additional, Imamura, Yoshinori, additional, Kiyota, Naomi, additional, Ito, Mitsuhiro, additional, and Minami, Hironobu, additional

Published
2024
Full Text
View/download PDF

7. Surgical outcomes of metastatic bone tumors in the extremities (Surgical outcomes of bone metastases)

Author

Hara, Hitomi, Sakai, Yoshitada, Kawamoto, Teruya, Fukase, Naomasa, Kawakami, Yohei, Takemori, Toshiyuki, Fujiwara, Shuichi, Kitayama, Kazumichi, Yahiro, Shunsuke, Miyamoto, Tomohiro, Kakutani, Kenichiro, Niikura, Takahiro, Miyawaki, Daisuke, Okada, Takuya, Sakashita, Akihiro, Imamura, Yoshinori, Sasaki, Ryohei, Kizawa, Yoshiyuki, Minami, Hironobu, Matsumoto, Tomoyuki, Matsushita, Takehiko, Kuroda, Ryosuke, and Akisue, Toshihiro

Published
2021
Full Text
View/download PDF

9. Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project

Author

Shimoyama, Rai, primary, Imamura, Yoshinori, additional, Uryu, Kiyoaki, additional, Mase, Takahiro, additional, Shiragami, Megumi, additional, Fujimura, Yoshiaki, additional, Hayashi, Maki, additional, Ohtaki, Megu, additional, Ohtani, Keiko, additional, Shinozaki, Nobuaki, additional, and Minami, Hironobu, additional

Published
2024
Full Text
View/download PDF

10. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).

Author

Goto, Hironobu, Oshikiri, Taro, Kato, Takashi, Nagatani, Yoshiaki, Funakoshi, Yohei, Koterazawa, Yasufumi, Sawada, Ryuichiro, Harada, Hitoshi, Urakawa, Naoki, Hasegawa, Hiroshi, Kanaji, Shingo, Yamashita, Kimihiro, Matsuda, Takeru, Minami, Hironobu, and Kakeji, Yoshihiro

Subjects
NIVOLUMAB, CISPLATIN, IPILIMUMAB, DOCETAXEL, ADJUVANT chemotherapy, ESOPHAGEAL cancer, NEOADJUVANT chemotherapy, CETUXIMAB
Abstract

Background: In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated. This study aims to elucidate the efficacy and safety of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. Methods: This study is a multi-institutional, single-arm, Phase II trial. We plan to recruit 130 esophageal squamous cell carcinoma patients, who have undergone preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. If the patient did not have a pathological complete response, nivolumab is started as a postoperative adjuvant therapy within 4–16 weeks after surgery. The nivolumab dose is 480 mg/day every four weeks. Nivolumab is administered for up to 12 months. The primary endpoint is disease-free survival; the secondary endpoints are overall survival, distant metastasis-free survival, and incidence of adverse events. Discussion: To our knowledge this study is the first trial establishing the efficacy of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. In Japan, preoperative adjuvant chemotherapy followed by surgery is a well-established standard treatment for resectable, locally advanced esophageal squamous cell carcinoma. Therefore, developing an effective postoperative adjuvant therapy has been essential for improving oncological outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models

Author

Saito, Yasuyuki, primary, Iida-Norita, Rie, additional, Afroj, Tania, additional, Refaat, Alaa, additional, Hazama, Daisuke, additional, Komori, Satomi, additional, Ohata, Shinya, additional, Takai, Tomoko, additional, Oduori, Okechi S., additional, Kotani, Takenori, additional, Funakoshi, Yohei, additional, Koma, Yu-Ichiro, additional, Murata, Yoji, additional, Yakushijin, Kimikazu, additional, Matsuoka, Hiroshi, additional, Minami, Hironobu, additional, Yokozaki, Hiroshi, additional, Manz, Markus G., additional, and Matozaki, Takashi, additional

Published
2023
Full Text
View/download PDF

12. Routinely Calculable Biomarkers Are Associated with the Development of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation

Author

Ichikawa, Hiroya, primary, Yakushijin, Kimikazu, additional, Tsuji, Takahiro, additional, Takemoto, Naoko, additional, Joyce, Miki, additional, Okazoe, Yuri, additional, Takahashi, Ruri, additional, Matsumoto, Sakuya, additional, Sakai, Rina, additional, Kurata, Keiji, additional, Kitao, Akihito, additional, Miyata, Yoshiharu, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Ito, Mitsuhiro, additional, Murayama, Tohru, additional, Matsuoka, Hiroshi, additional, and Minami, Hironobu, additional

Published
2023
Full Text
View/download PDF

13. The Efficacy of Bepotastine Besilate Compared with Hydroxyzine Pamoate for Preventing Infusion Reactions with First Dose of Rituximab in Non-Hodgkin Lymphoma Patients: Protocol for a Phase II, Double-Blind, Multicenter, and Randomized Trial (Preprint)

Author

Kitahiro, Yumi, primary, Yamamoto, Kazuhiro, additional, Yakushijin, Kimikazu, additional, Ioroi, Takeshi, additional, Tanda, Masaaki, additional, Itohara, Kotaro, additional, Omura, Tomohiro, additional, Minami, Hironobu, additional, and Yano, Ikuko, additional

Published
2023
Full Text
View/download PDF

14. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01)

Author

Uryu, Kiyoaki, primary, Imamura, Yoshinori, additional, Shimoyama, Rai, additional, Mase, Takahiro, additional, Fujimura, Yoshiaki, additional, Hayashi, Maki, additional, Ohtaki, Megu, additional, Otani, Keiko, additional, Hibino, Makoto, additional, Horiuchi, Shigeto, additional, Fukui, Tomoya, additional, Fukai, Ryuta, additional, Chihara, Yusuke, additional, Iwase, Akihiko, additional, Yamada, Noriko, additional, Tamura, Yukihiro, additional, Harada, Hiromasa, additional, Shinozaki, Nobuaki, additional, Tsuya, Asuka, additional, Fukuoka, Masahiro, additional, and Minami, Hironobu, additional

Published
2023
Full Text
View/download PDF

16. P10-2 Prognostic value of systemic inflammation in patients undergoing 1st-line chemotherapy for metastatic pancreatic cancer: Tokushukai REAl-world Data project

Author

Shimoyama, Rai, primary, Imamura, Yoshinori, additional, Uryu, Kiyoaki, additional, Mase, Takahiro, additional, Fujimura, Yoshiaki, additional, Hayashi, Maki, additional, Ohtaki, Megu, additional, Ohtani, Keiko, additional, Shinozaki, Nobuaki, additional, and Minami, Hironobu, additional

Published
2023
Full Text
View/download PDF

18. Effect of increase in heart rate after anthracycline chemotherapy on subsequent left ventricular dysfunction

Author

Kintsu, Masayuki, primary, Odajima, Susumu, additional, Takeuchi, Kimikazu, additional, Ichikawa, Yasushi, additional, Todo, Saki, additional, Ota, Eri, additional, Yamauchi, Yuki, additional, Shiraki, Hiroaki, additional, Yamashita, Kentaro, additional, Fukuda, Terunobu, additional, Hisamatsu, Eriko, additional, Minami, Hironobu, additional, Hirata, Ken-ichi, additional, and Tanaka, Hidekazu, additional

Published
2023
Full Text
View/download PDF

20. O16-5 Nivolumab for cancer of unknown primary (CUP): Initial results from an expanded access program (NivoCUP2, WJOG14620M)

Author

Tanizaki, Junko, primary, Yonemori, Kan, additional, Takiguchi, Yuichi, additional, Akiyoshi, Kohei, additional, Komine, Keigo, additional, Onozawa, Yusuke, additional, Sato, Mariko, additional, Hirata, Kenro, additional, Onoe, Takuma, additional, Ohkuma, Ryotaro, additional, Horita, Yosuke, additional, Minami, Hironobu, additional, Honda, Kazunori, additional, Suyama, Koichi, additional, Ito, Akihiko, additional, Chiba, Yasutaka, additional, Nishio, Kazuto, additional, and Hayashi, Hidetoshi, additional

Published
2023
Full Text
View/download PDF

21. MO36-2 Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP)

Author

Funakoshi, Yohei, primary, Tanizaki, Junko, additional, Yonemori, Kan, additional, Akiyoshi, Kohei, additional, Ueda, Hiroki, additional, Takiguchi, Yuichi, additional, Miura, Yuji, additional, Segawa, Yoshihiko, additional, Komine, Keigo, additional, Okikawa, Yoshiko, additional, Kidera, Yasuhiro, additional, Fukuoka, Kazuya, additional, Ito, Akihiko, additional, Chiba, Yasutaka, additional, Sakai, Kazuko, additional, Minami, Hironobu, additional, Nishio, Kazuto, additional, Nakagawa, Kazuhiko, additional, and Hayashi, Hidetoshi, additional

Published
2023
Full Text
View/download PDF

24. Biclonal Diffuse Large B-cell Lymphoma Commonly Characterized by Partial Trisomy 18q Involving MALT1 and BCL2

Author

Yamamoto, Katsuya, Kawamoto, Shinichiro, Chijiki, Ruri, Watanabe, Marika, Matsumoto, Sakuya, Kitao, Akihito, Mizutani, Yu, Kajimoto, Kazuyoshi, Hayashi, Yoshitake, Yakushijin, Kimikazu, and Minami, Hironobu

Subjects
BCL2, biclonal B-cell lymphoma, MALT1, diffuse large B-cell lymphoma, trisomy 18
Abstract

A 68-year-old man was admitted because of a left shoulder mass and swollen right testis. Pathological examinations indicated a diagnosis of diffuse large B-cell lymphoma (DLBCL) with the CD20+BCL6+MUM1+BCL2+CD10-MYC- phenotype in both lesions. G-banding of soft tissue showed 47,XY,+18, whereas testicular cells showed 47,X,+X,-Y,der (4) t (4;18) (p15;?),del (5) (q?),+13. Fluorescence in situ hybridization detected additional MALT1 and BCL2 signals in both lesions. Southern blot demonstrated different IGH rearrangements between the soft tissue and testis. The patient was diagnosed with biclonal DLBCL with different karyotypes but similar immunophenotypes. Partial trisomy 18q involving MALT1 and BCL2 may be commonly involved in the pathogenesis of this biclonal DLBCL.

Published
2023

27. Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia

Author

Ichikawa, Hiroya, primary, Yakushijin, Kimikazu, additional, Miyata, Yoshiharu, additional, Kanehira, Hirofumi, additional, Joyce, Miki, additional, Hirakawa, Yuri, additional, Matsumoto, Sakuya, additional, Nagao, Shigeki, additional, Sakai, Rina, additional, Kurata, Keiji, additional, Kitao, Akihito, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Ito, Mitsuhiro, additional, Murayama, Tohru, additional, Matsuoka, Hiroshi, additional, and Minami, Hironobu, additional

Published
2023
Full Text
View/download PDF

28. Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research

Author

Suto, Hirotaka, Funakoshi, Yohei, Nagatani, Yoshiaki, Imamura, Yoshinori, Toyoda, Masanori, Kiyota, Naomi, Matsumoto, Hisayuki, Tanaka, Shinwa, Takai, Ryo, Hasegawa, Hiroshi, Yamashita, Kimihiro, Matsuda, Takeru, Kakeji, Yoshihiro, and Minami, Hironobu

Subjects
Oncology, Experimental, Colorectal cancer -- Genetic aspects -- Care and treatment -- Models, Immunotherapy -- Research, Xenotransplantation -- Usage, Cancer -- Research, Microsatellite instability -- Research, Health
Abstract

Byline: Hirotaka. Suto, Yohei. Funakoshi, Yoshiaki. Nagatani, Yoshinori. Imamura, Masanori. Toyoda, Naomi. Kiyota, Hisayuki. Matsumoto, Shinwa. Tanaka, Ryo. Takai, Hiroshi. Hasegawa, Kimihiro. Yamashita, Takeru. Matsuda, Yoshihiro. Kakeji, Hironobu. Minami Context: [...]

Published
2021

29. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells

Author

Nagatani, Yoshiaki, Funakoshi, Yohei, Suto, Hirotaka, Imamura, Yoshinori, Toyoda, Masanori, Kiyota, Naomi, Yamashita, Kimihiro, and Minami, Hironobu

Subjects
Oncology, Experimental, Suppressor cells -- Health aspects -- Physiological aspects, Bone marrow cells -- Health aspects -- Physiological aspects, Immune response -- Research, Cancer -- Research, Immunosuppression -- Research, Health
Abstract

Byline: Yoshiaki. Nagatani, Yohei. Funakoshi, Hirotaka. Suto, Yoshinori. Imamura, Masanori. Toyoda, Naomi. Kiyota, Kimihiro. Yamashita, Hironobu. Minami Context: Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immune cells of [...]

Published
2021

30. Abstract P5-02-42: Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

Author

Mukohara, Toru, primary, Ozaki, Yukinori, additional, Kitano, Shigehisa, additional, Yamashita, Makiko, additional, Ikarashi, Daiki, additional, Tsurutani, Junji, additional, Iwasa, Tsutomu, additional, Takahashi, Masato, additional, Masuda, Norikazu, additional, Futamura, Manabu, additional, Minami, Hironobu, additional, Matsumoto, Koji, additional, Tanabe, Yuko, additional, Kawabata, Hidetaka, additional, Yoshimura, Kenichi, additional, and Takano, Toshimi, additional

Published
2023
Full Text
View/download PDF

31. Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study

Author

Mizutani, Yu, primary, Kawamoto, Shinichiro, additional, Takahashi, Michiko, additional, Doi, Hisayo, additional, Wakida, Kumiko, additional, Tabuchi, Satoko, additional, Tanda, Masaaki, additional, Soga, Akihiro, additional, Chijiki, Ruri, additional, Takakura, Hidetomo, additional, Kawaguchi, Koji, additional, Higashime, Ako, additional, Watanabe, Marika, additional, Ichikawa, Hiroya, additional, Matsumoto, Sakuya, additional, Sakai, Rina, additional, Goto, Hideaki, additional, Kurata, Keiji, additional, Kakiuchi, Seiji, additional, Miyata, Yoshiharu, additional, Uryu, Kiyoaki, additional, Inui, Yumiko, additional, Kitao, Akihito, additional, Yakushijin, Kimikazu, additional, Matsuoka, Hiroshi, additional, and Minami, Hironobu, additional

Published
2023
Full Text
View/download PDF

33. Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer

Author

Koyama, Taiji, Funakoshi, Yohei, Imamura, Yoshinori, Nishimura, Sho, Fujishima, Yoshimi, Toyoda, Masanori, Kiyota, Naomi, Tanino, Hirokazu, and Minami, Hironobu

Subjects
nontuberculous mycobacteria, nivolumab, anti-PD-1 antibody, Antineoplastic Agents, Immunological, breast cancer, Mycobacterium mageritense, Programmed Cell Death 1 Receptor, Humans, Female, Case Report, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Mycobacteriaceae
Abstract

Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immune-related adverse events (irAEs). Although irAEs are well recognized, the development of infectious diseases due to this treatment is not often observed. Some recent reports have indicated that patients who receive anti-PD-1 antibodies are at a higher risk for tuberculosis than others. However, reports on nontuberculous mycobacterial infection during anti-PD-1 antibody treatment are still rare. We herein report the first case of Mycobacterium mageritense infection during anti-PD-1 antibody treatment.

Published
2021

34. GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance

Author

Inase, Aki, primary, Maimaitili, Yimamu, additional, Kimbara, Shiro, additional, Mizutani, Yu, additional, Miyata, Yoshiharu, additional, Ohata, Shinya, additional, Matsumoto, Hisayuki, additional, Kitao, Akihito, additional, Sakai, Rina, additional, Kawaguchi, Koji, additional, Higashime, Ako, additional, Nagao, Shigeki, additional, Kurata, Keiji, additional, Goto, Hideaki, additional, Kawamoto, Shinichiro, additional, Yakushijin, Kimikazu, additional, Minami, Hironobu, additional, and Matsuoka, Hiroshi, additional

Published
2022
Full Text
View/download PDF

35. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

Author

Ozaki, Yukinori, primary, Tsurutani, Junji, additional, Mukohara, Toru, additional, Iwasa, Tsutomu, additional, Takahashi, Masato, additional, Tanabe, Yuko, additional, Kawabata, Hidetaka, additional, Masuda, Norikazu, additional, Futamura, Manabu, additional, Minami, Hironobu, additional, Matsumoto, Koji, additional, Yoshimura, Kenichi, additional, Kitano, Shigehisa, additional, and Takano, Toshimi, additional

Published
2022
Full Text
View/download PDF

36. Global longitudinal strain is superior to ejection fraction for long‐term follow‐up after allogeneic hematopoietic stem cell transplantation

Author

Watanabe, Marika, primary, Yakushijin, Kimikazu, additional, Tanaka, Hidekazu, additional, Chijiki, Ruri, additional, Saeki, Miki, additional, Hirakawa, Yuri, additional, Takakura, Hidetomo, additional, Usui, Yutaro, additional, Ichikawa, Hiroya, additional, Sakai, Rina, additional, Matsumoto, Sakuya, additional, Nagao, Shigeki, additional, Mizutani, Yu, additional, Kurata, Keiji, additional, Kitao, Akihito, additional, Miyata, Yoshiharu, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Ito, Mitsuhiro, additional, Matsuoka, Hiroshi, additional, and Minami, Hironobu, additional

Published
2022
Full Text
View/download PDF

37. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Author

Watanabe, Marika, primary, Yakushijin, Kimikazu, additional, Funakoshi, Yohei, additional, Ohji, Goh, additional, Ichikawa, Hiroya, additional, Sakai, Hironori, additional, Hojo, Wataru, additional, Saeki, Miki, additional, Hirakawa, Yuri, additional, Matsumoto, Sakuya, additional, Sakai, Rina, additional, Nagao, Shigeki, additional, Kitao, Akihito, additional, Miyata, Yoshiharu, additional, Koyama, Taiji, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Ito, Mitsuhiro, additional, Murayama, Tohru, additional, Matsuoka, Hiroshi, additional, and Minami, Hironobu, additional

Published
2022
Full Text
View/download PDF

38. Real-World Outcomes of Systemic Therapy in Japanese Patients with Cancer (Tokushukai REAl-World Data Project: TREAD): Study Protocol for a Nationwide Cohort Study

Author

Shimoyama, Rai, primary, Imamura, Yoshinori, additional, Uryu, Kiyoaki, additional, Mase, Takahiro, additional, Fujimura, Yoshiaki, additional, Hayashi, Maki, additional, Ohtaki, Megu, additional, Ohtani, Keiko, additional, Shinozaki, Nobuaki, additional, and Minami, Hironobu, additional

Published
2022
Full Text
View/download PDF

39. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Author

Rai, Shinya, primary, Kim, Won Seog, additional, Ando, Kiyoshi, additional, Choi, Ilseung, additional, Izutsu, Koji, additional, Tsukamoto, Norifumi, additional, Yokoyama, Masahiro, additional, Tsukasaki, Kunihiro, additional, Kuroda, Junya, additional, Ando, Jun, additional, Hidaka, Michihiro, additional, Koh, Youngil, additional, Shibayama, Hirohiko, additional, Uchida, Toshiki, additional, Yang, Deok Hwan, additional, Ishitsuka, Kenji, additional, Ishizawa, Kenichi, additional, Kim, Jin Seok, additional, Lee, Hong Ghi, additional, Minami, Hironobu, additional, Eom, Hyeon Seok, additional, Kurosawa, Mitsutoshi, additional, Lee, Jae Hoon, additional, Lee, Jong Seok, additional, Lee, Won Sik, additional, Nagai, Hirokazu, additional, Shindo, Takero, additional, Yoon, Dok Hyun, additional, Yoshida, Shinichiro, additional, Gillings, Mireille, additional, Onogi, Hiroshi, additional, and Tobinai, Kensei, additional

Published
2022
Full Text
View/download PDF

40. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status

Author

Tanioka, Maki, Sasaki, Masaoki, Shimomura, Akihiko, Fujishima, Makoto, Doi, Mihoko, Matsuura, Kazuo, Sakuma, Toshiko, Yoshimura, Kenichi, Saeki, Toshiaki, Ohara, Masahiro, Tsurutani, Junji, Watatani, Masahiro, Takano, Toshimi, Kawabata, Hidetaka, Mukai, Hirofumi, Naito, Yoichi, Hirokaga, Koichi, Takao, Shintaro, and Minami, Hironobu

Published
2014
Full Text
View/download PDF

47. Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Author

MS Medische Oncologie, Cancer, Externen Med. Onco, MS Hematologie, Infection & Immunity, Stein, Eytan M, DeAngelo, Daniel J, Chromik, Jörg, Chatterjee, Manik, Bauer, Sebastian, Lin, Chia-Chi, Suarez, Cristina, De Vos, Filip, Steeghs, Neeltje, Cassier, Phillippe A, Tai, David, Kiladjian, Jean-Jacques, Yamamoto, Noboru, Mous, Rogier, Esteve, Jordi, Minami, Hironobu, Ferretti, Stéphane, Guerreiro, Nelson, Meille, Christophe, Radhakrishnan, Rajkumar, Pereira, Bernard, Mariconti, Luisa, Halilovic, Ensar, Fabre, Claire, Carpio, Cecilia, MS Medische Oncologie, Cancer, Externen Med. Onco, MS Hematologie, Infection & Immunity, Stein, Eytan M, DeAngelo, Daniel J, Chromik, Jörg, Chatterjee, Manik, Bauer, Sebastian, Lin, Chia-Chi, Suarez, Cristina, De Vos, Filip, Steeghs, Neeltje, Cassier, Phillippe A, Tai, David, Kiladjian, Jean-Jacques, Yamamoto, Noboru, Mous, Rogier, Esteve, Jordi, Minami, Hironobu, Ferretti, Stéphane, Guerreiro, Nelson, Meille, Christophe, Radhakrishnan, Rajkumar, Pereira, Bernard, Mariconti, Luisa, Halilovic, Ensar, Fabre, Claire, and Carpio, Cecilia

Published
2022

48. Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination

Author

Funakoshi, Yohei, primary, Yakushijin, Kimikazu, additional, Ohji, Goh, additional, Hojo, Wataru, additional, Sakai, Hironori, additional, Watanabe, Marika, additional, Kitao, Akihito, additional, Miyata, Yoshiharu, additional, Saito, Yasuyuki, additional, Kawamoto, Shinichiro, additional, Yamamoto, Katsuya, additional, Ito, Mitsuhiro, additional, Koyama, Taiji, additional, Imamura, Yoshinori, additional, Kiyota, Naomi, additional, Matsuoka, Hiroshi, additional, Mori, Yasuko, additional, and Minami, Hironobu, additional

Published
2022
Full Text
View/download PDF

49. Abstract 6143: Tumor immune microenvironment in salivary gland cancer

Author

Nagatani, Yoshiaki, primary, Kiyota, Naomi, additional, Imamura, Yoshinori, additional, Koyama, Taiji, additional, Funakoshi, Yohei, additional, Komatsu, Masato, additional, Teshima, Masanori, additional, Nibu, Ken-Ichi, additional, Sakai, Kazuko, additional, Nishio, Kazuto, additional, Shimomura, Manami, additional, Nakatsura, Tetsuya, additional, Ikarashi, Daiki, additional, Nakayama, Takayuki, additional, Kitano, Shigehisa, additional, and Minami, Hironobu, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results